Claims
- 1. A method for detecting and determining species source of eubacterial DNA in a sample, comprising:
amplifying template DNA in a sample using a real-time polymerase chain reaction (PCR), wherein the PCR employs primers and at least two fluorogenic probes, wherein the primers amplify a segment of a S. aureus 16S rRNA gene comprising a conserved region and a first divergent region, wherein the conserved region comprises at least 18 contiguous nucleotides which are at least 80% identical among at least 10 eubacterial species wherein the first divergent region comprises at least 10 contiguous nucleotides and differs by at least 3 nucleotides from a second divergent region found in Rhizobium japonicum 16S rRNA gene; wherein each of the fluorogenic probes comprises a reporter dye and a quencher dye, a first of the two fluorogenic probes hybridizing to the conserved region and the second of the two fluorogenic probes hybridizing to a third divergent region of a first species of eubacteria, wherein the reporter dyes of the first and the second probes have non-overlapping emission spectra; monitoring fluorescence emissions of the reporter dyes; determining presence of eubacteria in the sample if emissions characteristic of the reporter dye of the first probe are detected; and determining presence of the first species of eubacteria in the sample if emissions characteristic of the reporter dye on the second probe are detected.
- 2. The method of claim 1 wherein a third fluorogenic probe is employed in the real-time PCR, wherein the third fluorogenic probe hybridizes to a fourth divergent region of 16S rRNA gene in a second species of eubacteria and wherein the reporter dye of the third fluorogenic probe has a non-overlapping emission spectrum from the reporter dyes of the first and second probes.
- 3. The method of claim 2 wherein a fourth fluorogenic probe is employed in the real-time PCR, wherein the fourth fluorogenic probe hybridizes to a fifth divergent region of 16S rRNA gene in a third species of eubacteria and wherein the reporter dye of the fourth fluorogenic probe has a non-overlapping emission spectrum from the reporter dyes of the first, second, and third probes.
- 4. The method of claim 1 wherein the segment of S. aureus 16S rRNA gene comprises nucleotides 890 to 1051.
- 5. The method of claim 1 wherein the conserved region of S. aureus 16S rRNA gene comprises nucleotides 1002 to 1024.
- 6. The method of claim 1 wherein the first divergent region comprises nucleotides 945 to 978 of S. aureus 16S rRNA gene.
- 7. The method of claim 1 wherein the sample is a treated blood sample.
- 8. The method of claim 7 wherein the blood sample is from a patient suspected of systemic bacteremia.
- 9. The method of claim 7 wherein the sample was treated to extract DNA from cells.
- 10. The method of claim 1 wherein the sample is urine.
- 11. The method of claim 1 wherein the sample is cerebrospinal fluid.
- 12. The method of claim 1 wherein the primers comprise primers p890F and p1033R (SEQ ID NO: 1 and 2, respectively.)
- 13. The method of claim 1 wherein the segment amplified is at least 125 bp.
- 14. The method of claim 1 wherein the segment amplified is at least 150 bp.
- 15. The method of claim 1 wherein the segment amplified is at least 160 bp.
- 16. A method for detecting and determining species source of eubacterial DNA in a sample, comprising:
filtering a real-time PCR reaction mixture to remove double stranded DNA contaminants having a length of ≧125 bp to form a filtrate, wherein the PCR reaction mixture comprises primers and at least two fluorogenic probes, wherein the primers amplify a segment of a S. aureus 16S rRNA gene comprising a conserved region and a first divergent region, wherein the conserved region comprises at least 18 contiguous nucleotides which are at least 80% identical among at least 10 eubacterial species, wherein the first divergent region comprises at least 10 contiguous nucleotides and differs by at least 3 nucleotides from a second divergent region of Rhizobium japonicum 16S rRNA gene, wherein each of the probes comprises a reporter dye and a quencher dye, a first of the two fluorogenic probes hybridizing to the conserved region and the second of the two fluorogenic probes hybridizing to a third divergent region of a first eubacterial species, wherein the reporter dyes of the first and the second probes have non-overlapping emission spectra; adding a sample comprising template DNA to the filtrate; amplifying template DNA in the filtrate; monitoring fluorescence emissions of the reporter dyes; determining presence of eubacteria in the sample if emissions characteristic of the reporter dye of the first probe are detected; and determining presence of the first species of eubacteria in the sample if emissions characteristic of the reporter dye on the second probe are detected.
- 17. The method of claim 16 wherein a third fluorogenic probe is present in the real-time PCR reaction mixture, wherein the third fluorogenic probe hybridizes to a fourth divergent region of a 16S rRNA gene in a second species of eubacteria and wherein the reporter dye of the third fluorogenic probe has a non-overlapping emission spectrum from the first and second probes.
- 18. The method of claim 17 wherein a fourth fluorogenic probe is present in the real-time PCR reaction mixture, wherein the fourth fluorogenic probe hybridizes to a fifth divergent region of a 16S rRNA gene in a third species of eubacteria and wherein the reporter dye of the fourth fluorogenic probe has a non-overlapping emission spectrum from the first, second, and third probes.
- 19. The method of claim 16 wherein the segment comprises nucleotides 890 to 1051 of S. aureus 16S rRNA gene.
- 20. The method of claim 16 wherein the conserved region comprises nucleotides 1002 to 1024 of S. aureus 16S rRNA gene.
- 21. The method of claim 16 wherein the first divergent region comprises nucleotides 945 to 978 of S. aureus 16S rRNA gene.
- 22. The method of claim 16 wherein the sample is a treated blood sample.
- 23. The method of claim 22 wherein the blood sample is from a patient suspected of systemic bacteremia.
- 24. The method of claim 22 wherein the sample was treated to extract DNA therefrom.
- 25. The method of claim 16 wherein the sample is urine.
- 26. The method of claim 16 wherein the sample is cerebrospinal fluid.
- 27. The method of claim 16 wherein the primers comprise primers p890F and p1033R (SEQ ID NO: 1 and 2, respectively.)
- 28. The method of claim 16 wherein the segment amplified is at least 125 bp.
- 29. The method of claim 16 wherein the segment amplified is at least 150 bp.
- 30. The method of claim 16 wherein the segment amplified is at least 160 bp.
- 31. The method of claim 16 wherein the conserved region is at least 80% identical among at least 14 eubacterial species.
- 32. The method of claim 1 wherein the conserved region is at least 80% identical among at least 14 eubacterial species.
- 33. The method of claim 1 wherein the first divergent region comprises at least 15 contiguous nucleotides.
- 34. The method of claim 1 wherein the first divergent region comprises at least 20 contiguous nucleotides.
- 35. The method of claim 1 wherein the first divergent region comprises at least 25 contiguous nucleotides.
- 36. The method of claim 1 wherein the first divergent region comprises at least 30 contiguous nucleotides.
- 37. The method of claim 16 wherein the first divergent region comprises at least 15 contiguous nucleotides.
- 38. The method of claim 16 wherein the first divergent region comprises at least 20 contiguous nucleotides.
- 39. The method of claim 16 wherein the first divergent region comprises at least 25 contiguous nucleotides.
- 40. The method of claim 16 wherein the first divergent region comprises at least 30 contiguous nucleotides.
- 41. The method of claim 1 wherein the first divergent region differs by at least 4 nucleotides from the second divergent region.
- 42. The method of claim 16 wherein the first divergent region differs by at least 4 nucleotides from the second divergent region.
- 43-52. (Canceled)
Parent Case Info
[0001] This application claims priority to and incorporates by reference co-pending provisional application Serial No. 60/272,642 filed Mar. 1, 2001, the disclosure of which is expressly incorporated herein.
Government Interests
[0002] The invention was made under funding from National Institutes of Health grant 3M01RR00052-39-5(S1). The U.S. government therefore retains certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60272642 |
Mar 2001 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10085134 |
Mar 2002 |
US |
Child |
10743384 |
Dec 2003 |
US |